Semax vs Selank: How They Differ

Semax and Selank are two synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. They share an institutional origin, appear together in many search queries, and are studied in the neuroscience literature — but they are distinct compounds with different molecular structures and research profiles that do not overlap. The core difference: Semax is investigated primarily in neuroprotection and cognitive modulation; Selank in anxiety regulation and stress response.

Molecular structure: where each compound comes from

Semax is a synthetic analogue of the ACTH(4-7) fragment, derived from adrenocorticotropic hormone. The sequence documented in the literature is Met-Glu-His-Phe-Pro-Gly-Pro. The addition of a Pro-Gly-Pro tripeptide at the carboxyl terminus stabilises the compound against enzymatic degradation, allowing studies to work with a more predictable half-life than the natural ACTH fragment provides.

Selank derives from tuftsin: an endogenous tetrapeptide (Thr-Lys-Pro-Arg) produced from immunoglobulin G, with documented immunomodulatory properties going back to the 1970s. The sequence of Selank in the published literature is Thr-Lys-Pro-Arg-Pro-Gly-Pro. As with Semax, the Pro-Gly-Pro extension was added to increase metabolic stability and reduce the rate of degradation in in vivo models.

The fact that one derives from a stress-hormone fragment and the other from an immunomodulatory peptide largely explains why their research profiles point in such different directions. Two compounds from the same institute can share a structural motif — the Pro-Gly-Pro stabilising tail — while activating entirely different receptors and pathways in the nervous system.

What the research literature says about Semax

Semax research clusters around two main lines, both documented in publications available through PubMed.

The first is acute neuroprotection. Studies from the Institute of Molecular Genetics evaluated the compound in models of cerebral ischemia and oxidative neuronal damage. These studies formed the basis for clinical trials developed in the Russian hospital context, where Semax was investigated in stroke and neurological recovery settings.

The second line is modulation of brain-derived neurotrophic factor (BDNF). BDNF is a protein involved in synaptic plasticity, neuronal survival, and memory consolidation. A 2006 paper by Dolotov and colleagues described Semax's effect on BDNF expression in the rat central nervous system, directing subsequent research toward cognitive functions and attentional deficit models.

A separate body of research describes Semax effects in relation to opioid peptides and nociception, areas where the compound's ACTH-derived origin is particularly relevant. Some published animal studies also examine effects on the retina in neurodegeneration models.

The profile that emerges from reviewed animal models is one of activation: observed effects on dopaminergic and serotonergic systems, with a greater presence in neurological recovery studies than in anxiety or sedation research. That orientation toward activation is what distinguishes Semax from Selank in the comparative summaries found in the specialist literature.

What the research literature says about Selank

Selank literature points in a different direction. The primary focus is anxiety studies and stress regulation, with a clinical base that includes trials published across several phases by researchers at the Institute of Pharmacology of Moscow and other Russian centres.

The most documented mechanism is modulation of the GABAergic system. Publications by Seredenin and colleagues available on PubMed describe effects on plasma tryptophan levels and stress-response markers in animal models. Clinical trials compared Selank against benzodiazepines in generalised anxiety disorder models; the results reported in the same literature show anxiety symptom reduction without the typical sedative effects of the reference drugs.

That distinction — anxiolytic activity without marked sedation — appears most frequently in published comparisons and is what sets Selank apart from other compounds studied in the same field. The benzodiazepine comparison is significant because it was conducted in controlled clinical settings, which gives Selank one of the more substantial clinical evidence bases among research peptides focused on anxiety modulation.

Because tuftsin — Selank's parent compound — has documented effects on immune regulation, a secondary strand of Selank research explores immunomodulatory effects: changes in interleukin levels and lymphocyte activity in stressed animal models. These effects are separate from the central anxiolytic profile and represent a less-explored line in the published literature.

The differences between the two compounds

Summarised from the literature, the concrete differences between Semax and Selank are:

• Structural origin: Semax comes from an ACTH fragment (a hormone related to the stress axis); Selank comes from tuftsin (an immunomodulatory peptide). This difference determines which receptors each one activates and which signalling pathways it modulates in study models.
• Primary research area: Semax concentrates its publications in acute neuroprotection and BDNF modulation; Selank in anxiolytic regulation and modulation of the GABAergic system.
• Profile observed in animal models: Semax shows a more marked activation profile on dopaminergic and serotonergic systems; Selank shows a softer modulatory profile, associated with stress-response reduction without sedation.
• Available clinical base: Selank has published trials in generalised anxiety disorder with direct comparison against benzodiazepines; Semax trials concentrate primarily on acute neurological pathology such as ischemia and post-stroke recovery.

None of these observations is a recommendation for use. They are differences the scientific literature identifies in controlled research contexts, across animal models and clinical trials in specific populations.

Researchers choosing between these compounds for a study programme would look first at which outcome domain aligns with their model. A neuroprotection study and an anxiety model ask different questions; Semax and Selank are, in the published literature, answers to different questions.

How they are supplied for research

PeptoClinic supplies Semax and Selank as research material with an independent laboratory certificate of analysis (COA) included with each shipment. The standard specification is ≥99% purity determined by HPLC.

For projects destined for Argentina, the quotation process includes review of lot purity specification, laboratory documentation, and import requirements as laboratory reference material. Batch reports from analysed lots are published on the PeptoClinic quality page, with verification links available for the reports the laboratory enables directly.

The full catalogue includes both compounds alongside the documentation for each lot. Quotations are issued after review of compound, purity specification, quantity, and destination — a researcher contacts the technical team and receives a written quotation, normally within one business day.

Laboratory research material only

All material supplied by PeptoClinic is intended exclusively for laboratory research (Research Use Only, RUO): in vitro studies and controlled research models.

Semax and Selank are not approved for human or veterinary consumption by any regulatory authority, including the FDA, ANMAT, or their regional equivalents. They are not medicines, supplements or over-the-counter products. PeptoClinic is not a pharmacy, a clinic or a provider of human or veterinary use protocols. Inquiries about dosing, administration routes or protocols for human use are not answered.